Scholarlink

Purpose <p>Nanotechnology has revolutionized the field of diagnostics and therapy in oncology, particularly for brain tumors and metastases. Radiolabelled nanoparticles, due to their ability to cross the blood-brain barrier and selectively accumulate in tumor tissues, emerge as key tools for both diagnosis and treatment. We studied their integration with SPECT and PET, which has improved imaging sensitivity and specificity. Their application in nanotheranostics opens new perspectives for more effective diagnostic and therapeutic strategies.</p> Methods <p>A systematic literature review was conducted using PubMed, Scopus and Embase databases (last update November 2024), with keywords related to brain tumors, nanoparticles, radiopharmaceuticals, PET, SPECT, and therapy. Relevant studies on the application of radiolabelled nanotechnologies for both diagnosis and treatment of primary and metastatic brain tumors were selected.</p> Results <p>In diagnostics, liposomes, mesoporous silica nanoparticles, and gold nanostructures radiolabelled with isotopes such as Zirconium-89, Gallium-68, and Iodine-124 have demonstrated high multimodal imaging capabilities with PET and SPECT. On the therapeutic side, radiolabelled nanoparticles with Rhenium-188, Yttrium-90, and Lutetium-177 have shown effective intra-tumoral retention and potential targeted therapeutic effects, reducing systemic toxicity compared to conventional treatments.</p> Conclusions <p>Radiolabelled nanoparticles represent a significant advancement in the management of brain tumors, combining advanced diagnostics and targeted therapy in a theranostic approach. While preclinical results are promising, challenges remain regarding long-term safety, large-scale production, and regulatory approval for clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radionuclide-based nanotechnologies in brain tumors: an updated overview

  • 期刊论文

  • 发表日期：

    2025年6月16日

查看全文
  • Maria Librando,
  • Elisabetta Perrone,
  • Greta Celesti,
  • Andrea Marongiu,
  • Susanna Maria Francesca Nuvoli,
  • Stefano Panareo,
  • Angela Spanu,
  • Laura Evangelista

摘要

Purpose

Nanotechnology has revolutionized the field of diagnostics and therapy in oncology, particularly for brain tumors and metastases. Radiolabelled nanoparticles, due to their ability to cross the blood-brain barrier and selectively accumulate in tumor tissues, emerge as key tools for both diagnosis and treatment. We studied their integration with SPECT and PET, which has improved imaging sensitivity and specificity. Their application in nanotheranostics opens new perspectives for more effective diagnostic and therapeutic strategies.

Methods

A systematic literature review was conducted using PubMed, Scopus and Embase databases (last update November 2024), with keywords related to brain tumors, nanoparticles, radiopharmaceuticals, PET, SPECT, and therapy. Relevant studies on the application of radiolabelled nanotechnologies for both diagnosis and treatment of primary and metastatic brain tumors were selected.

Results

In diagnostics, liposomes, mesoporous silica nanoparticles, and gold nanostructures radiolabelled with isotopes such as Zirconium-89, Gallium-68, and Iodine-124 have demonstrated high multimodal imaging capabilities with PET and SPECT. On the therapeutic side, radiolabelled nanoparticles with Rhenium-188, Yttrium-90, and Lutetium-177 have shown effective intra-tumoral retention and potential targeted therapeutic effects, reducing systemic toxicity compared to conventional treatments.

Conclusions

Radiolabelled nanoparticles represent a significant advancement in the management of brain tumors, combining advanced diagnostics and targeted therapy in a theranostic approach. While preclinical results are promising, challenges remain regarding long-term safety, large-scale production, and regulatory approval for clinical application.